Stock INAB IN8BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials IN8bio, Inc.

Equities

INAB

US45674E1091

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
1.01 USD 0.00% Intraday chart for IN8bio, Inc. +1.00% -26.81%
05-09 IN8bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 82.33 56.6 59.67 44.46 - -
Enterprise Value (EV) 1 82.33 56.6 59.67 44.46 44.46 44.46
P/E ratio - - - -1.57 x -2 x -2.04 x
Yield - - - - - -
Capitalization / Revenue - - - - 6.44 x 1.24 x
EV / Revenue - - - - 6.44 x 1.24 x
EV / EBITDA - - - - - -
EV / FCF -5.96 x - - -1.49 x -1.43 x -1.33 x
FCF Yield -16.8% - - -67.3% -69.7% -75.1%
Price to Book - - - - - -
Nbr of stocks (in thousands) 18,755 24,502 43,241 44,020 - -
Reference price 2 4.390 2.310 1.380 1.010 1.010 1.010
Announcement Date 17/03/22 30/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 6.9 35.75
EBITDA - - - - - - -
EBIT 1 - -14.65 -28.52 -30.34 -31.58 -36.65 -24.92
Operating Margin - - - - - -531.1% -69.7%
Earnings before Tax (EBT) 1 - - - - -30.85 -35.38 -37.75
Net income 1 -8.557 - - - -30.85 -35.38 -37.75
Net margin - - - - - -512.8% -105.58%
EPS 2 -3.020 - - - -0.6450 -0.5050 -0.4950
Free Cash Flow 1 - -13.82 - - -29.9 -31 -33.4
FCF margin - - - - - -449.28% -93.43%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 31/03/21 17/03/22 30/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -5.849 -6.145 -7.179 -7.399 -7.798 -7.525 -7.715 -7.169 -7.928 -8.562 -7.629 -7.925 -8.236 - -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - - - - - - - - - -8.562 -7.55 -7.81 -8.188 - -
Net income 1 - - - - - - - - - -8.562 -7.55 -7.81 -8.188 - -
Net margin - - - - - - - - - - - - - - -
EPS 2 - - - - - - - - - -0.2000 -0.1750 -0.1650 -0.1350 - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 17/03/22 12/05/22 12/08/22 10/11/22 30/03/23 12/05/23 10/08/23 09/11/23 14/03/24 09/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -13.8 - - -29.9 -31 -33.4
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share 2 - - - - -0.9200 -0.7200 -0.5700
Capex 1 - - - - 0.16 0.33 0.4
Capex / Sales - - - - - 4.71% 1.12%
Announcement Date 31/03/21 17/03/22 30/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.01 USD
Average target price
7.6 USD
Spread / Average Target
+652.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
IN8BIO, INC. Stock IN8bio, Inc.
-26.81% 44.46M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. INAB Stock
  4. Financials IN8bio, Inc.